# Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

> **NCT00668122** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 212 (actual)

## Conditions studied

- Urinary Tract Infection

## Interventions

- **DRUG:** Cipro XR (Ciprofloxacin, BAYQ3939)
- **DRUG:** Cipro IR (Ciprofloxacin, BAYQ3939)

## Key facts

- **NCT ID:** NCT00668122
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2009-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668122, "Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00668122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*